Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,117 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06652243RecruitingEarly Phase 1
Cell therapy for advanced liver cancer with GPC3 protein
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06211114RecruitingPhase 2
Immunotherapy and targeted drug for advanced collecting duct kidney cancer
This trial tests a combination of immunotherapy and a targeted drug (axitinib) for people with advanced collecting duct carcinoma, a rare type of kidney cancer. The goal is to see if this treatment can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT06475118Recruiting
Blood tests and scans to measure muscle loss in liver cancer
This study looks at whether measuring certain proteins in your blood (myokines) can help detect muscle loss (sarcopenia) in people with liver cancer, and compares these blood tests to special CT scans. If you're newly diagnosed with liver cancer and have a CT scan already, you may be able to join.
ReimsAges 18 years+ - NCT07619599RecruitingPhase 1
PET Scan to Track Lung Cancer Treatment Response
This study uses a special PET imaging scan to help doctors see how well pembrolizumab (an immunotherapy drug) is working against advanced non-small cell lung cancer. You'll receive the scan along with your regular pembrolizumab treatment and possible radiation therapy to help measure treatment response.
Duarte, CaliforniaAges 18 years+ - NCT07613151Recruiting
Lobular breast cancer with low hormone receptors
This study looks at a rare type of breast cancer called invasive lobular carcinoma that has low or no hormone receptors. The goal is to learn more about how this cancer behaves, which may help improve future treatments.
PadovaAges 18 years+ - NCT07617753RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Recurrent Ovarian Cancer
This trial tests a new type of cell therapy using modified natural killer cells (CAR-NK cells) that are trained to attack ovarian cancer cells. It's designed for patients whose cancer has come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT06709417RecruitingPhase 2
Immunotherapy plus chemo and radiation for advanced esophageal cancer
This trial is testing whether giving a combination of an immunotherapy drug (sintilimab) with chemotherapy, followed by radiation plus more chemotherapy (concurrent chemoradiotherapy), can help people with advanced esophageal cancer that cannot be removed surgically. The goal is to see if this approach shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 20–75 - NCT07607769Recruiting
Tremelimumab and Durvalumab for Untreated Advanced Liver Cancer
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
AnconaAges 18–100 - NCT06444009RecruitingPhase 2
Immunotherapy and chemo before surgery for head and neck cancer
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Chengdu, SichuanAges 18–75 - NCT07610551Recruiting
Combination therapy for advanced liver cancer
This trial studies whether combining three treatments—an immunotherapy drug (Atezo), a blood-vessel-blocking drug (Bev), and a radioactive bead treatment (SIRT-Y90)—can help patients with advanced liver cancer that cannot be surgically removed. The goal is to see if using all three together works better than using fewer treatments.
Xi’an, ShanxiAges 18 years+ - NCT07606508Recruiting
Tracking skin cancer patients starting systemic treatment
This study follows patients newly diagnosed with cutaneous squamous cell carcinoma (a type of skin cancer) who are beginning systemic treatment (medicine that affects the whole body). Researchers want to understand how these treatments work and track patient outcomes over time.
AmiensAges 18 years+ - NCT06609850Recruiting
Comparing TACE plus lenvatinib with or without ablation for recurrent liver cancer
This trial compares two treatments for people whose liver cancer has come back (recurrent intermediate-stage hepatocellular carcinoma). One group gets TACE plus lenvatinib (a targeted therapy), the other gets TACE plus lenvatinib plus ablation (a procedure that destroys tumors with heat or cold). The goal is to see which combination works better.
Beijing, None SelectedAges 18–75 - NCT06609863Recruiting
Triple therapy for large liver cancer tumors
This trial tests combining a special type of chemo delivered directly to the liver (dTACE-HAIC) with two immunotherapy drugs (bevacizumab and atezolizumab) for people with huge liver cancer tumors (10 cm or larger). The goal is to see if this combination can shrink tumors and improve outcomes.
Beijing, None SelectedAges 18–75 - NCT06644430Recruiting
Burning lung spots plus systemic therapy for liver cancer
This trial tests whether burning away a few cancer spots in the lungs (called ablation) can help people with liver cancer who are already on a systemic treatment. If you have stable liver cancer and only a few lung spots that haven't grown, you may be eligible.
Beijing, Beijing MunicipalityAges 18–80 - NCT07598955RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Relapsed Thymoma or Thymic Carcinoma
This trial tests a new type of immune cell therapy called CAR-NK cells, which are designed to fight thymoma or thymic carcinoma (cancers of the thymus gland) that has come back or stopped responding to prior treatments. The goal is to see if these engineered cells can shrink tumors and help patients live longer.
Shenzhen, GuangdongAges 18–75 - NCT07595770RecruitingPhase 2
New immunotherapy combined with chemotherapy and radiation for esophageal cancer
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT07596654Recruiting
Surgery versus chemotherapy for early-stage small cell esophageal cancer
This study compares how well surgery works compared to chemotherapy and radiation for treating small cell cancer that started in the esophagus and hasn't spread far. Researchers will examine which approach helps patients live longer.
Nanjing, JiangsuAges 18 years+ - NCT05185739RecruitingPhase 2
Pembrolizumab and lenvatinib before liver surgery for resectable cancer
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
BirminghamAges 18 years+ - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Goodyear, ArizonaAges 18 years+ - NCT07590024RecruitingPhase 3
Personalized Cancer Treatment Guidance for Nasopharyngeal Cancer
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
Beijing, Beijing MunicipalityAges 18–65 - NCT07578116RecruitingPhase 3
Adding surgery and radiation for her2-positive breast cancer with a few spread spots
This trial tests whether adding surgery and radiation to the usual HER2-targeted treatment helps people with breast cancer that has spread to a few spots. You must have HER2-positive cancer that is newly spread, and you must be able to receive radiation to all tumor sites.
Jonesboro, ArkansasAges 18 years+ - NCT07586124RecruitingPhase 2
Immunotherapy plus antibody drug for advanced head and neck cancer
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07581821RecruitingPhase 2
Immunotherapy plus targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
Zhuhai, GuangdongAges 18–65 - NCT05668962RecruitingPhase 2
Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Washington D.C., District of ColumbiaAges 12 years+
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,117 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.